These data provide evidence in support of a leukemogenic role for BCR-JAK2 fusion in myeloproliferative disorders, including CML, and complements data provided by the first case report by Griesinger et al. [11]. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.